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30Abstract—Vitamin D is a neuroactive steroid. Its genomic
actions are mediated via the active form of vitamin D,
1,25(OH)2D3, binding to the vitamin D receptor (VDR). The
VDR emerges in the rat mesencephalon at embryonic day
12, representing the peak period of dopaminergic cell birth.
Our prior studies reveal that developmental vitamin D
(DVD)-deﬁciency alters the ontogeny of dopaminergic neu-
rons in the developingmesencephalon. There is also consis-
tent evidence from others that 1,25(OH)2D3 promotes the
survival of dopaminergic neurons in models of dopaminer-
gic toxicity. In both developmental and toxicological studies
it has been proposed that 1,25(OH)2D3 may modulate the dif-
ferentiation and maturation of dopaminergic neurons; how-
ever, to date there is lack of direct evidence. The aim of the
current study is to investigate this both in vitro using a
human SH-SY5Y cell line transfected with rodent VDR and
in vivo using a DVD-deﬁcient model. Here we show that in
VDR-expressing SH-SY5Y cells, 1,25(OH)2D3 signiﬁcantly
increased production of tyrosine hydroxylase (TH), the
rate-limiting enzyme in dopamine synthesis. This eﬀect
was dose- and time-dependent, but was not due to an
increase in TH-positive cell number, nor was it due to the pro-
duction of trophic survival factors for dopamine neurons
such as glial-derived neurotrophic factor (GDNF). In accor-
dance with 1,25(OH)2D3’s anti-proliferative actions in the
brain, 1,25(OH)2D3 reduced the percentage of dividing cells
from approximately 15–10%. Given the recently reported role
of N-cadherin in the direct diﬀerentiation of dopaminergic
neurons, we examined here whether it may be elevated by
1,25(OH)2D3. We conﬁrmed this in vitro and more impor-
tantly, we showed DVD-deﬁciency decreases N-cadherin
expression in the embryonic mesencephalon. In summary,
in our in vitro model we have shown 1,25(OH)2D3 increases
TH expression, decreases proliferation and elevates
N-cadherin, a potential factor that mediates these processes.http://dx.doi.org/10.1016/j.neuroscience.2015.07.048
0306-4522/ 2015 Published by Elsevier Ltd. on behalf of IBRO.
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1Accordingly all of these ﬁndings are reversed in the develop-
ing brain in our DVD-deﬁciency model. Remarkably our ﬁnd-
ings in the DVD-deﬁciency model phenocopy those found in
a recent model where N-cadherin was regionally ablated
from the mesencephalon. This study has, for the ﬁrst time,
shown that vitamin D directly modulates TH expression
and strongly suggests N-cadherin may be a plausible media-
tor of this process both in vitro and in vivo. Our ﬁndings may
help to explain epidemiological data linking DVD deﬁciency
with schizophrenia.  2015 Published by Elsevier Ltd. on
behalf of IBRO.
Key words: 1,25(OH)2D3, tyrosine hydroxylase, dopamine,
development, developmental vitamin D (DVD)-deﬁciency,
proliferation, N-cadherin, vitamin D receptor.31
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41INTRODUCTION
Vitamin D is a steroid hormone and exerts diverse
physiological functions that extend beyond its classical
role in calcium and bone homeostasis (Jones et al.,
1998). Several lines of evidence indicate vitamin D is
important for both developing and adult brains (Eyles
et al., 2009, 2010, 2013). In particular, our recent ﬁndings
reveal the role that vitamin D may play in developing
dopaminergic neurons (Cui et al., 2010, 2013; Eyles
et al., 2014). Based on epidemiological ﬁndings, prenatal
vitamin D deﬁciency has been identiﬁed as a risk factor for
disorders associated with abnormalities in dopamine sig-
naling. A Danish case–control study has shown that
neonatal vitamin D status was signiﬁcantly associated
with the subsequent risk of schizophrenia (McGrath
et al., 2010). The latest meta-analysis of all published
observational studies that have measured vitamin D
levels in schizophrenic patients conﬁrms a strong associ-
ation between vitamin D deﬁciency and schizophrenia
(Valipour et al., 2014). Low levels of vitamin D have also
been detected in patients with Parkinson’s disease
(Newmark and Newmark, 2007; Evatt et al., 2008, 2011;
Knekt et al., 2010). Outcomes from a randomized clinical
trial of vitamin D supplementation in patients with
Parkinson disease is eagerly awaited (Suzuki et al.,
2013).
A model of depleting female Sprague–Dawley rats of
vitamin D before conception until birth has proved useful
for investigating the neurobiological eﬀects of vitamin D
deﬁciency during brain development. One consistent
ﬁnding from this developmental vitamin D (DVD)-deﬁcient
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24 July 2015model is an alteration in dopamine signaling. Although
vitamin D levels return to normal by the 2nd post-natal
week, the adult oﬀspring display enhanced sensitivity to
the locomotor inducing eﬀects of the dopamine releasing
agent, amphetamine (Kesby et al., 2010), and also to the
dopamine receptor antagonist, haloperidol (Kesby et al.,
2006).When theneonatal brains from thismodel are exam-
ined, DVD-deﬁcient oﬀspring have reduced expression of
the dopamine-degradation enzyme catechol-O-methyl
transferase (COMT)which converts thedopaminemetabo-
lite dihydroxyphenylacetic acid (DOPAC) to homovanillic
acid (HVA). Accordingly the ratio of DOPAC/HVA is
reduced indicating dopamine turnover is abnormal in the
neonatal forebrain (Kesby et al., 2009). At earlier develop-
mental stages, DVD-deﬁcient embryos display a reduced
expression of the crucial dopamine speciﬁcation factors,
Nurr1 and p57kip2, in mesencephalon (Cui et al., 2010).
Finally DVD-deﬁciency has also very recently been shown
to down-regulate TH gene and protein expression in the
embryonic brains of female mice (Hawes et al., 2015). In
summary, these ﬁndings strongly suggest that vitamin D
modulates the orderly early development of dopaminergic
systems.
In the adult brain, vitamin D has been recognized as a
neuroprotective agent for dopaminergic neurons. Multiple
studies have shown that treatment with the active form of
vitamin D, 1,25(OH)2D3, protects against the adverse
eﬀects of the well-known dopaminergic toxin, 6-
hydroxydopamine (6-OHDA) (Wang et al., 2001; Smith
et al., 2006; Cass et al., 2012, 2014). Cass et al. showed
that long-term 1,25(OH)2D3 treatment increases the level
of glial-derived neurotrophic factor (GDNF) in the dam-
aged striatum. In addition to its well-known trophic actions
on dopaminergic neurons, GDNF has also been found to
be able to restore evoked dopamine levels after 6-OHDA-
induced striatal damage (Cass and Manning, 1999). It
was postulated that GDNF at least partially contributed
to the protective eﬀect of 1,25(OH)2D3 in these animal
models (Smith et al., 2006; Cass et al., 2014).
Interestingly, although it has been suggested that tyrosine
hydroxylase (TH), a rate limiting enzyme for dopamine
synthesis, might be directly modulated by 1,25(OH)2D3
this was never established. 1,25(OH)2D3 treatment before
or after local cerebral 6-OHDA administration partially
restores TH protein and TH-immunoreactive ﬁbers in the
striatum and substantia nigra (SN) as well as increases
GDNF protein (Sanchez et al., 2009). 1,25(OH)2D3 has
also been shown to increase TH-positive cell number in
the SN of 6-OHDA-lesioned mice (Kim et al., 2006).
Although the authors of these last two studies stated that
1,25(OH)2D3-induced alterations in GDNF or microglia
were responsible for its neuroprotective eﬀects on
dopaminergic neurons, they also could not rule out a more
direct eﬀect on TH expression. To date only one study has
shown that 1,25(OH)2D3 can directly increase the expres-
sion of TH mRNA but this was in adrenal medullary cells
(Puchacz et al., 1996).
1,25(OH)2D3 exerts its genomic functions via the
vitamin D receptor (VDR). The VDR is a member of a
larger nuclear steroid receptor family, well-known for
their actions in the developing brain. The VDR isPlease cite this article in press as: Cui X et al. Vitamin D regulates tyrosine h
(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048expressed as early as embryonic day (E) 12 in
developing rat mesencephalon (Veenstra et al., 1998).
We conﬁrm this and have shown punctate VDR staining
in the nucleus of dopaminergic neurons at this age
(Cui et al., 2013). The time window from E12 to E15 rep-
resents the critical period for the birth of dopaminergic
neurons in Sprague–Dawley rats (Gates et al., 2006).
DVD-deﬁciency during this period leads to a reduction in
mesencephalic expression of both early dopaminergic
speciﬁcation factors, Nurr1 and p57kip, and more mature
dopaminergic neuronal markers such as TH (Cui et al.,
2010). It would therefore appear that vitamin D signaling
is strategically positioned to aﬀect the ontogeny of devel-
oping dopaminergic neurons.
1,25(OH)2D3 inhibits cell proliferation and promotes
diﬀerentiation by multiple mechanisms. In cancer cells
that express the VDR this has been frequently linked to
the expression of E-cadherin (Palmer et al., 2001;
Ordonez-Moran et al., 2008; Lopes et al., 2012). E-
cadherin is only transiently expressed in developing dien-
cephalon and mesencephalon between E9.5 and E15
(Shimamura and Takeichi, 1992) and we could not detect
it in developing mesencephalon by western blot (data no
shown). However the classical cadherin family includes
E-, N-, P-, and R-cadherin members. N-cadherin is a neu-
ral adhesion molecule that plays important role in neuro-
genesis and of particular interest to our group,
dopamine neuron development (Sakane and Miyamoto,
2013). Therefore we have investigated the expression of
N-cadherin both in our in vitro and in vivo models.
Although evidence from adult and developing brain
indicates that 1,25(OH)2D3 modulates TH expression
either in developing or adult dopamine neurons
subjected to neurotoxin exposure there is no evidence
that 1,25(OH)2D3 can directly modulate TH expression
or promote dopamine neuron diﬀerentiation. In addition,
the underlying mechanisms behind this process remain
opaque. We therefore have generated an in vitro model
where the rat VDR is expressed in SH-SY5Y cells to
examine this question. SH-SY5Y cells have been widely
used to study dopamine neuronal diﬀerentiation and
dopamine neuron survival in cell-based models of
Parkinson’s disease (Xie et al., 2010). Next, we have also
used mesencephalon from our DVD-deﬁcient rat embryos
to see if the developmental absence of vitamin D reverses
these processes in the developing brain. We aimed to
clarify whether: (1) 1,25(OH)2D3 directly regulates TH
expression; (2) 1,25(OH)2D3 regulates the diﬀerentiation
and maturation of dopamine neurons, and (3) suggest
potential mechanisms involved in these processes.EXPERIMENTAL PROCEDURES
Cell line
Human SH-SY5Y cells were purchased from Sigma–
Aldrich (MO, USA). Cells were cultured in Dulbecco’s
Modiﬁed Eagles Medium (DMEM)/F12 supplemented
with 10% fetal calf serum (Invitrogen Life technology
Australia, Victoria, Australia), L-glutamax (Invitrogen),
100 U/ml penicillin and 0.1 mg/ml streptomycin (Sigma).ydroxylase expression: N-cadherin a possible mediator. Neuroscience
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24 July 2015After stable transfection, the VDR-transfected cells were
cultured in the presence of geneticin (Invitrogen) at a
concentration of 500 lg/ml.
Cloning of VDR
Total RNA from adult rat kidney was prepared using
RNeasy Plus mini kit (Qiagen, Hildon, Germany) and
cDNA synthesized using SuperScript III First-Strand
Synthesis System (Invitrogen) according to the
manufacturer’s protocol. 0.2 lM of full–length rat VDR
primers (Forward: 5’ CTACTCACCCTGCTCCTTCAG 3’,
Reverse: 5’ GTCAGGAGATCTCATTGCCG 3’) and 1U
Phusion Hot Star II DNA Polymerase (Thermo Scientiﬁc,
IL, USA) were employed for PCR. The PCR products
were sequenced and the full-length VDR inserted into
pTarget vector (Promega Corporation, MI, USA).
Transfections
The pTarget-VDR construct was transfected into human
SH-SY5Y cells using Lipofectamine 2000 (Invitrogen) in
serum free Opti-MEM (Invitrogen) in 6-well plates. 18 h
after transfection, the serum-free medium was replaced
with normal growth medium. 48 h later cells were
passaged at a 1:10 dilution into fresh growth medium in
the presence of 2 mg/ml geneticin. The medium was
changed every 3 days. Three weeks later, geneticin-
resistant single-cell colonies were selected and
expanded. VDR over-expression was conﬁrmed by
western blot (Data not shown). Long-term maintenance
of stable transfectants was performed in the presence of
0.5 mg/ml geneticin. All experiments with transfected
cells were conducted within 10 passages.
1,25(OH)2D3 treatment
VDR-expressing SH-SY5Y cells were seeded into 24-well
plates at a concentration of 6  104 cells per well. Cells
were allowed to settle for 2 days and then induced to
diﬀerentiate in DMEM/F12 with 1% FCS in the presence
of 10 lM retinoic acid (RA)(Sigma) for 7 days. Then
1,25(OH)2D3 (Calcitriol, Calbiochem, Life Technology),
was applied at varying concentrations in serum-free
medium with B27 supplement (Invitrogen) and cells
cultured for another 7 days. The medium containing
these factors was changed every 3–4 days. This
treatment regime is depicted in Fig. 2.
DVD-deﬁcient rat model
Brieﬂy, female Sprague–Dawley rats were fed with a diet
depleted of cholecalciferol but with normal calcium and
phosphorous. The rats were housed under a 12-h
light/dark cycle using incandescent lighting free of
ultraviolet radiation in the vitamin D action spectrum
(290–315 nm). After 6 weeks, serum vitamin D depletion
was conﬁrmed prior to mating (25(OH)D3 < 0.34 ng/ml)
(Eyles et al., 2011). The resulting dams were housed
under these conditions until the birth of pups. Control ani-
mals were kept under standard lighting conditions and
supplied with standard rat chow containing vitamin D.
Both vitamin D deplete dams and oﬀspring remainedPlease cite this article in press as: Cui X et al. Vitamin D regulates tyrosine h
(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048normocalcemic. This model has been described in detail
elsewhere (Eyles et al., 2009). The embryonic (E18)
brains were dissected and frozen on dry ice for western
blot. All experiments were conducted with the ethical
approval of the University of Queensland.Western blot
VDR-expressing SH-SY5Y cells were collected in lysis
buﬀer (150 mM NaCl, 20 mM HEPES, 2 mM EDTA,
pH7.4) containing protease inhibitor cocktail (Roche
Diagnostics Australia, castle Hill, NSW, Australia).
Protein concentrations were determined using a micro
BCA assay (Peirce, Bonn, Germany) and 5 lg of total
protein per lane was loaded. Proteins were resolved by
SDS–PAGE using 4–12% NUPAGE Bis-Tris gels
(Invitrogen) before being transferred to polyvinylidene
ﬂuoride (PVDF) membranes at 400 mA for two hours.
The PVDF membranes were blocked in 5% non-fat milk
and then probed with primary antibodies, anti-VDR
antibody (D-6, 0.2 lg/mL) (Santa Cruz, TX, USA), anti-
TH (0.1 lg/mL) (Millipore, Darmstadt, Germany), or anti-
N-cadherin (1:2500, Millipore) at 4 C overnight and
then incubated with horseradish peroxidise (HRP)-
labeled goat anti-mouse secondary antibody (1:5000,
Cell Signalling Technology, MA, USA) for one hour.
Transferred protein bands were visualized using
standard chemiluminescence techniques (Thermo
Scientiﬁc Pierce). Membranes were then washed and
reprobed with anti-glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) antibody (1:50,000, Millipore)
as a loading control. The ﬁlms were scanned and the
intensity of the bands assessed using Quantity One
software (Bio-Rad Laboratories Pty., Ltd. Life Science,
Australia).Real time PCR
Cells were collected and RNA was isolated and cDNA
synthesis was performed as described above. The
following primers were used: TH (Forward, 50-GCAGTT
CTCGCAGGACATTG-30 and reverse, 50-TGGATGCGT
GAGGCATAGC-30), GDNF (Forward, 50-CTGGGCTATG
AAACCAAGGA-30 and reverse, 50-GACAGGTCATCATC
AAAGGC-30) and GAPDH (Forward, 50-TTTACATGTTT
CCAATATGATTCCAC-30 and reverse, 50-TTGTCATAC
TTCTCATGGTTCACAC-30). Real time PCR was perfo-
rmed on LightCycler 480 system (Roche Diagnostics,
Castle Hill, Australia). The PCR conditions were as
follows: a denaturation step at 95 C for 10 min followed
by ampliﬁcation for 40 cycles (95 C for 10 s, and 60 C
for 1 min). The relative expression of genes of interest
was normalized to GAPDH as a housekeeping gene
using the comparative threshold method.Stereological cell counting
Cells were grown on coverslips. On day 7 of 1,25(OH)2D3
treatment, cell culture medium was replaced with serum
free medium containing 20 lM of 5-ethynyl-20-
deoxyuridine (EdU), and 3 h later, EdU incorporation
was detected using Click-iT EdU Imaging kit (Invitrogen)ydroxylase expression: N-cadherin a possible mediator. Neuroscience
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Fig. 1. TH expression is modulated by 1,25(OH)2D3. VDR-expressing SH-SY5Y cells were treated with retinoid acid (RA) (10 lM) for 7 days and
then 1,25(OH)2D3 for 7 days. 1,25(OH)2D3 increases (A) TH protein in a dose-dependent manner [0.1–100 nM; F(5,18) = 27.82, p< 0.001, n= 4]
relative to vehicle (D 0.04% ethanol); (B) dopamine synthesis (t= 6.448, n= 3, **p< 0.01) and (C) TH mRNA (t= 3.056, n= 4, *p< 0.05).
Data = mean ± SEM.
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24 July 2015according to manufacturer’s instructions. Brieﬂy, cells
were ﬁxed and rinsed twice with phosphate-buﬀered
saline (PBS) containing 3% bovine serum albumin
(BSA, Sigma) and incubated with 150 lL EdU-Click
reaction-mix for 30 min at room temperature, and then
rinsed with 3% BSA/PBS. Hoechst 33342 was used to
stain the nuclei to count all cells. The coverslips were
mounted on glass slides with ﬂuorescence mounting
medium (DAKO, Glostrup, Denmark). EdU and Hoechst
33342-positive cells were counted using
stereoinvestigator software and unbiased stereological
methods.304
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315Flow cytometry to determine TH-positive cell number
Cells were collected before diﬀerentiation
(Undiﬀerentiated cells), 3 and 7 days after RA treatment,
and then 1, 3 and 7 days after 1,25(OH)2D3 (20 nM)
(Fig. 2A). Ethanol (0.04%) was used as vehicle. Cells
were directly collected in lysis buﬀer for western blot or
digested by 0.05% trypsin (Invitrogen) and ﬁxed as
above. After ﬁxation, cells were blocked with 3% BSA
and incubated with a rabbit monoclonal anti-TH antibody
(1:4000) (Abcam) for 30 min. After being washed withPlease cite this article in press as: Cui X et al. Vitamin D regulates tyrosine h
(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048PBS, cells were incubated with Alexa 488 anti-Rabbit
antibody (Invitrogen) for 20 min. All incubations were
done on ice. The cells were then stained with Hoechst
33342 and then subjected to ﬂow cytometry.Measuring dopamine levels
VDR-expressing cells were seeded in a 24-well plate and
treated with RA for 7 days and then 1,25(OH)2D3 for
7 days. Cells in each well were collected in 100 lL of
lysis buﬀer containing 0.1 M perchloric acid and
50 ng/ml deoxypinephrine (DE) used as an internal
standard. 50 lL of cell lysate was centrifuged at
13,000 rpm for 10 min and 35 lL of supernatant were
ﬁltered by a 0.45 lM polypropylene syringe ﬁlter (Agilent
Technologies, Inc., CA, USA) and injected directly into a
high-pressure liquid chromatography system consisting
of an autosampler, an isocratic HPLC pump (Model
1100, Agilent Technologies, Inc.), a Sunﬁre C18
column, 4.6 mm  150 mm, 5 lM; (Waters Corporation,
MA, USA) and a Coulochem III (ESA Laboratories, Inc.,
MA, USA) electrochemical detector. The mobile phase
consisted of a 10% acetonitrile/75 mM potassium
dihydrogen phosphate buﬀer containing 25 lM EDTAydroxylase expression: N-cadherin a possible mediator. Neuroscience
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Fig. 2. TH expression is modulated by 1,25(OH)2D3 in a time-dependent manner. (A) VDR-expressing SH-SY5Y and wild type SH-SY5Y cells were
harvested at 3 and 7 days after RA (10 lM) treatment (RA3 and RA7) or at 1, 3 and 7 days after 20 nM 1,25(OH)2D3 (+D1,+D3,+D7) or after
vehicle treatment (D1, D3, D7). (B) In VDR-expressing SH-SY5Y cells 1,25(OH)2D3 treatment for 7 days signiﬁcantly increases TH expression
compared to levels after 7 days of RA treatment (F(8,18) = 7.29, n= 3, *p< 0.05). (C) 1,25(OH)2D3 did not change the percentage of TH-positive
cells (n= 4). Data = mean ± SEM.
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24 July 2015and 1.7 mM octane sulfonic acid adjusted to pH 3 with
phosphoric acid delivered at 1 mL/min. Detector settings
were as follows: conditioning cell (Model 5020, ESA
Laboratories, Inc., MA) +350 mV; analytical cell (Model
5014B, ESA Laboratories, Inc., MA) with the ﬁrst and
second electrodes maintained at 150 and +250 mV
respectively. Data were quantiﬁed by calculating peak-
height ratios for each speciﬁc analyte relative to an
internal standard, DE. Data were processed with
Chemstation software (Rev B.01.03, Agilent
Technologies, Inc.). Samples were corrected for dilution
and expressed as nanogram per gram (ng/g) protein.342
343
344
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347Statistical analysis
Unpaired t-tests were used to analyze the eﬀects of
1,25(OH)2D3 on dopamine production; TH mRNA
expression; GDNF expression; dividing or total cellPlease cite this article in press as: Cui X et al. Vitamin D regulates tyrosine h
(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048number and N-Cadherin expression. For the eﬀects of
1,25(OH)2D3 concentration or the eﬀects of 1,25(OH)2D3
over time on TH protein production, statistical analyses
were performed by an analysis of variance (ANOVA)
followed by post hoc tukey’s tests. Signiﬁcance level
was set at p< 0.05.
RESULTS
Eﬀect of 1,25(OH)2D3 on TH expression and activity
in vitro
1,25(OH)2D3 signiﬁcantly increased TH protein in VDR-
expressing SH-SY5Y cells in a dose-dependent manner
(Fig. 1A, F(5,18) = 27.82, p < 0.001, n= 4).
The optimal 1,25(OH)2D3 dose proved to be 20 nM. This
dose was used in all further cell-based experiments.
Dopamine, the product of TH, was also increased
10-fold in cell lysates (Fig. 1B, t = 6.448, p < 0.01,ydroxylase expression: N-cadherin a possible mediator. Neuroscience
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24 July 2015n= 3). TH mRNA was also signiﬁcantly enhanced by
1,25(OH)2D3 (Fig. 1C, t = 3.056, p < 0.05, n= 4).
Next we examined the time-dependent nature of TH
protein expression in VDR-expressing SH-SY5Y cells.
Cells were treated with RA for 7 days and 1,25(OH)2D3
at 20 nM for 7 days with media changed on days 3 and
6. The cells were collected at 3 and 7 days after RA
treatment and then 1, 3 and 7 days after vitamin D
treatment (Fig. 2A). In undiﬀerentiated cells, no TH
protein was observed. TH protein increased with RA
treatment. In VDR-expressing SH-SY5Y, the addition of
1,25(OH)2D3 progressively further increased TH
expression which became signiﬁcant after 7 days of
treatment compared to the last day of RA treatment
(Fig. 2B, F(8,18) = 7.29, p< 0.05, n= 3; RA7 vs.
+D7, p< 0.05). By contrast, the ethanol vehicle
produced no further increase in TH. To investigate
whether this 1,25(OH)2D3 – induced increase in TH
expression in VDR-expressing SH-SY5Y was due to an
increase in TH production per se or TH-expressing cell
number the percentage of cells expressing TH was
determined using ﬂow cytometry. We clearly showed
that the use of RA increased TH-positive cell number;
however 1,25(OH)2D3 had no further eﬀect (Fig. 2C).
This suggests the 1,25(OH)2D3 – mediated increase in
TH levels reﬂects an increase in expression, rather than
an increase in TH-positive cells.410
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4191,25(OH)2D3 does not alter GDNF expression in vitro
GDNF is a neurotrophic factor for dopaminergic neurons
and multiple lines of evidence have indicated that
1,25(OH)2D3 may directly modulate GDNF expression
(Naveilhan et al., 1996; Sanchez et al., 2002). In our dif-
ferentiated cells the GDNF transcript was thus examined
in the presence of 1,25(OH)2D3 but no alteration was
observed (Fig. 3, t= 0.2843, p = 0.7857, n= 4).420
421
422
423
424
4251,25(OH)2D3 reduces cell proliferation in vitro
We have previously shown that 1,25(OH)2D3 has potent
anti-proliferative eﬀects on primary hippocampal
neurons (Brown et al., 2003). In line with our previous-D +D
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Fig. 3. 1,25(OH)2D3 does not alter the expression of GDNF mRNA.
VDR-expressing SH-SY5Y cells were induced to diﬀerentiate by
addition of 10 lM RA for 7 days and then 20 nM 1,25(OH)2D3 (+D)
or vehicle (D: 0.04% ethanol) for 7 days. RNA was isolated and
GDNF expression was examined by real-time PCR (t= 0.2843,
p= 0.7857, n= 4).
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(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048ﬁnding, 1,25(OH)2D3 signiﬁcantly reduced the number of
dividing cells in culture by 30 per cent (Fig. 4A,
t= 5.195, p< 0.01, n= 4). It is reasonable to expect
that total number might therefore also be decreased; how-
ever, the total number of cells was not altered as
assessed by unbiased stereological cell counting tech-
niques (Fig. 4B).1,25(OH)2D3 increases N-cadherin expression
N-cadherin is a neural adhesion molecule that plays
important role in the neurogenesis of dopamine neurons
(Sakane and Miyamoto, 2013). In our current study,
1,25(OH)2D3 increased N-cadherin protein in VDR-
expressing SH-SY5Y cells (Fig. 5A, t= 2.476,
p< 0.05, n= 4). When we examined N-cadherin protein
in the mesencephalon from DVD-deﬁcient embryonic
brains, accordingly, it was signiﬁcantly reduced (Fig. 5B,
t= 3.304, p< 0.05, n= 3).DISCUSSION
There are several novel and important ﬁndings in this
study. First, we provide unambiguous evidence that
1,25(OH)2D3 promotes an increase in TH expression
and dopamine in neuroblastoma cells transfected with
the rodent VDR. This regulation is dose and time-
dependent and does not reﬂect any change in TH cell
number. Second, this increase in TH expression is not
associated with increased trophic eﬀects of GDNF at
least in this culture system. Third, we show that
1,25(OH)2D3 inhibits the proliferation of VDR-expressing
SHSY-5Y cells. Fourth, we ﬁnd that 1,25(OH)2D3
enhances that expression of N-cadherin, a neural
adhesion molecule important in dopaminergic neuron
diﬀerentiation and maturation. Finally when these factors
were investigated in vivo in developing neurons from our
DVD-deﬁciency model, accordingly, we observe the
reverse ﬁndings. A comparison of these ﬁndings from
our in vitro model of 1,25(OH)2D3 administration
compared with current and previously published ﬁndings
from our in vivo model of DVD-deﬁciency is presented in
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Fig. 4. The eﬀect of 1,25(OH)2D3 on proliferation. VDR-expressing
SH-SY5Y cells were treated with RA (10 lM) for 7 days and then
1,25(OH)2D3 (20 nM) (+D) or vehicle (D: 0.04% ethanol) for
7 days. EdU was applied on day 7 of 1,25(OH)2D3 treatment. 1,
25(OH)2D3 (A) reduces EdU incorporation (t= 5.195, n= 4,
**p< 0.01), but (B) does not alter total cell number (t= 0.2781,
n= 4, p= 0.7841). Data = mean ± SEM.
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Fig. 5. N-cadherin is modulated by 1,25(OH)2D3. (A) VDR-express-
ing SH-SY5Y were diﬀerentiated in the presence of RA (10 lM) for
7 days and then 1,25(OH)2D3 (20 nM) (+D) or vehicle (D: 0.04%
ethanol) for 24 h. Cells were collected and subjected to western blot.
1,25(OH)2D3 increases N-cadherin protein in VDR-expressing SH-
SY5Y cells in vitro (t= 2.476, n= 4, *p< 0.05) (B) DVD-deﬁciency
reduces N-cadherin protein in vivo (t= 3.304, n= 3, *p< 0.05).
Data = mean ± SEM.
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24 July 20151,25(OH)2D3 directly modulates TH expression in
neuronal cells
In our in vitro model, SH-SY5Y cells were ﬁrst pre-treated
with RA. This promoted approximately 12% of these cells
to diﬀerentiate and produce the dopaminergic marker TH.
Subsequent treatment with 1,25(OH)2D3 did not further
increase the overall percentage of TH-positive cells in
culture. However it clearly increased the production of
not only the TH protein and its transcript but also its
product dopamine, indicating this increase in TH is
functional. The optimal 1,25(OH)2D3 dose was 20 nM.
The response relationship is best described as an
‘‘inverted U’’ dose response. This dose and this dose-
relationship is entirely consistent with numerous
previous studies examining the eﬀects of this steroid
in vitro (Kelly et al., 1985; Ryhanen et al., 1998; Toell
et al., 2000; Chattopadhyay et al., 2003; Wu et al.,
2007) .
Consistent with 1,25(OH)2D3 having no eﬀect on TH-
positive cell number were the ﬁndings from unbiased
cell counting indicating that 1,25(OH)2D3 also had noTable 1. Vitamin D mediates alterations in N-cadherin, proliferation an
where 1,25(OH)2D3 is present in vitro with ﬁndings in the developing
compared with ﬁndings in which N-cadherin is regionally knocked out
In vitro (1,25(OH)2D3) In vivo (DVD-d
N-cadherin " ;
Cell proliferation ; "
(Eyles et al., 2
Cui et al., 2007
TH " ;
(Cui et al., 201
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(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048eﬀect on total cell number in culture. This further
suggests that the 1,25(OH)2D3 mediated increase in TH
and dopamine results from 1,25(OH)2D3 acting as a
diﬀerentiation agent on TH-positive neurons to increase
neuronal maturation and subsequent dopamine
production rather than increasing TH cell number or
survival (see below). The idea that 1,25(OH)2D3 could
promote aspects of neuronal maturation such as neurite
outgrowth in primary neuronal cultures (Brown et al.,
2003) as well as in neuroblastomas (Agholme et al.,
2010) has been made previously. Only one previous
study has reported that 1,25(OH)2D3 may directly
increase TH expression but this was in adrenal medullary
cells (Puchacz et al., 1996). Unfortunately only TH mRNA
levels were examined in that study, with neither TH pro-
tein nor TH-positive cell number examined.
A number of studies have shown that 1,25(OH)2D3 can
act as a neuroprotective agent for dopaminergic neurons
(Wang et al., 2001; Cass et al., 2006; Smith et al., 2006;
Sanchez et al., 2009; Cass et al., 2012, 2014). These data
and the epidemiological ﬁndings linking low levels of vita-
min D with increased risk of Parkinson’s disease (PD)
(Newmark and Newmark, 2007; Evatt et al., 2008, 2011;
Knekt et al., 2010; Peterson et al., 2013) have led to a clin-
ical trials of vitamin D in this disease. The initial ﬁndings
are very encouraging; the patients on placebo continued
to have a steady worsening on neurological outcomes
whereas those who took vitamin D (1200IU/day) had no
further progression in PD symptoms (Suzuki et al.,
2013). These results strongly suggest that vitamin D sta-
tus inﬂuences disease progression. Progression of PD
symptoms is associated with the degeneration of
dopaminergic neurons. As previously outlined, preclinical
studies in neurotoxicity animal models of this disease con-
ﬁrm that 1,25(OH)2D3 can restore dopamine levels in stria-
tum and ameliorate dopamine neuron death induced by
intra-cerebral administration of 6-OHDA (Wang et al.,
2001; Smith et al., 2006; Sanchez et al., 2009; Cass
et al., 2012, 2014). Cass et al. and Sanchez et al. have
showed that vitamin D increases GDNF in the lesioned
striatum indicating this trophic agent may be the mediating
factor for vitamin D’s neuroprotective actions on dopamine
neurons. 1,25(OH)2D3 has also been shown to reduce
dopaminergic neuronal death induced by 6-OHDA in pri-
mary mesencephalic cultures by increasing GDNF
expression (Orme et al., 2013). Therefore the evidence
that GDNF acts as a trophic factor for DA neurons in the
presence of toxic agents would appear strong. For thesed TH expression: comparison between ﬁndings presented here
brain where vitamin D is removed from the maternal diet and
eﬁciency) Regional N-cadherin knock-out
(Sakane and Miyamoto, 2013)
;
003; Ko et al., 2004;
)
"
(Dopaminergic progenitors)
0)
;
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24 July 2015reasons we also examined whether GDNF expression
may be a mediating factor in our in vitro model. The clear
absence of any eﬀect on GDNF expression in our in vitro
system suggests this factor may be more relevant to
1,25(OH)2D3’s actions in dopaminergic systems in the
presence of active toxicity.
1,25(OH)2D3 regulates the transcription of a variety of
genes via its receptor, the VDR. After ligand binding, the
VDR forms a heterodimer with the retinoid X receptor
(RXR). This complex binds to a vitamin D response
element (VDRE) in the regulatory region of the target
gene (Haussler et al., 1998). Our results suggesting a
direct eﬀect on TH expression may possibly be mediated
through this classical genomic function. Using the multi-
genome analysis of positions and patterns of elements
of regulation (MAPPER) search engine, we identiﬁed mul-
tiple putative VDREs within 10 kb from the 5’upstream
DNA sequence for the TH promoter (Marinescu et al.,
2005). Further investigations are warranted to explore
whether the VDREs on the promoter of TH are functional
via a technique such as chromatin immunoprecipitation
(ChIP). Indeed, other members of the same nuclear ster-
oid family as 1,25(OH)2D3 such as RA and estrogen have
been reported to modulate TH expression through their
respective response elements, the retinoic acid respon-
sive element (RARE) or the estrogen responsive element
(ERE) within the RXR complex binding to the promoter of
TH (Maharjan et al., 2005; Jeong et al., 2006). It is thus
plausible that some similar mechanisms may be operating
for 1,25(OH)2D3.583
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6101,25(OH)2D3 and cell proliferation
The ﬁnding that 1,25(OH)2D3 acts as a diﬀerentiation
agent for neurons is no longer surprising (McGrath
et al., 2001). Our results here indicating that
1,25(OH)2D3 decreases the number of dividing neurob-
lastomas is consistent with our previous ﬁndings showing
that 1,25(OH)2D3 reduces BrdU incorporation in hip-
pocampal progenitors (Brown et al., 2003). Further sup-
porting evidence comes from the study of neurospheres
which are formed when embryonic brain is dispersed
and cultured under the appropriate conditions. This neu-
rosphere number is directly proportional to number of
dividing cells (Reynolds and Rietze, 2005) and we have
shown that the addition of 1,25(OH)2D3 to neurospheres
in culture reduces neurosphere number (Cui et al.,
2007). Furthermore, previous evidence from our DVD-
deﬁcient rat model is also consistent with these ﬁndings.
In the developmental absence of vitamin D, DVD-
deﬁcient embryos have increased mitotic cells throughout
the embryonic brain (Eyles et al., 2003; Ko et al., 2004)
and increased neurosphere number (Cui et al., 2007).
DVD-deﬁciency also alters the corresponding expression
proﬁle of genes regulating mitosis in the brain (Ko et al.,
2004). In this later study results from pathway speciﬁc
arrays showed that 48% of genes related to mitosis were
up-regulated in the DVD-deﬁcient developing brain. In
addition, key cell-cycle modulators such as cyclins C
and B, as well as the cyclin-dependent kinase inhibitorPlease cite this article in press as: Cui X et al. Vitamin D regulates tyrosine h
(2015), http://dx.doi.org/10.1016/j.neuroscience.2015.07.048P21 cip1 are down-regulated in the DVD-deﬁcient devel-
oping rat (Ko et al., 2004). These cyclins and cyclin-
dependent kinase inhibitors play a key role on modulating
cell cycle progression. These factors have also been
shown to be altered by 1,25(OH)2D3 in this cell line.
Gumireddy et al. showed that 1,25(OH)2D3 and its ana-
logs regulate P21cip1 and reduce BrdU incorporation by
25–50% in SH-SY5Y cells (Gumireddy et al., 2003a,b).
1,25(OH)2D3 and its analogs have also been found to inhi-
bit the proliferation of human SH-SY5Y cells (Celli et al.,
1999; Stio et al., 2001).
A reduction in cell division as shown here in our in vitro
model may also be expected to produce a reduction in cell
number. However using unbiased cell counting techniques
the total cell number appeared to be normal. It is plausible
that once cells have undergone substantial diﬀerentiation
due to the exposure to both RA and 1,25(OH)2D3 for
7 days each, 1,25(OH)2D3 may act as a survival-
promoting factor. This ﬁnding is alluded to by the data of
Brewer et al., who showed that 1,25(OH)2D3 protects
hippocampal neuron against the toxicity of N-methyl-D-
asparate (NMDA) or glutamate toxicity (Brewer et al.,
2001). Alternately it is also possible that vitamin D reduces
the programedelimination of cells in ourmodel. This seems
unlikely however as vitamin D is pro-apoptotic (Krishnan
and Feldman, 2011). After 14 days in culture the percent-
age of dividing cells is only 15% in vehicle treated cells
(Fig. 4). Given the variance in the estimation of total cell
numbers it is unlikely a 5% reduction in cell number due
to less dividing cells in vitaminD treated cultureswould lead
to a signiﬁcant reduction in total cell numbers.1,25(OH)2D3 – induced diﬀerentiation of
dopaminergic neurons is possibly mediated by
N-cadherin
Cadherins are cell adhesion molecules that are important
in the formation and maintenance of diverse tissue. The
classical cadherins E, P and N are expressed in distinct
tissue types and display separate functions during
development. For instance, E-cadherin is expressed in
all epithelial tissue and contributes to the orientation of
cell polarity in epithelium. N-cadherin is mainly
expressed in neural tissue and muscles (Halbleib and
Nelson, 2006). Vitamin D modulates the expression of
cadherins in a tissue-dependent manor. 1,25(OH)2D3
increases E-cadherin levels in colon carcinoma cells
(Palmer et al., 2001) and in contrast, down-regulates N
and P-cadherin in breast cancer cells (Pendas-Franco
et al., 2007), Our result showed that 1,25(OH)2D3
increased N-cadherin in neuroblastomas and DVD-
deﬁciency reduced its level in embryonic mesencephalon.
N-cadherin is known not only to contribute to the
maintenance of tissue structure but also to cortical
neurogenesis (Zhang et al., 2010) and, of greater impor-
tance here, dopamine neuron diﬀerentiation. Regional
speciﬁc loss of N-cadherin in mouse mesencephalon
results in a signiﬁcant expansion of dopamine progenitors
due to a reduction in their exit from the cell cycle (Sakane
and Miyamoto, 2013). Therefore less dopamineydroxylase expression: N-cadherin a possible mediator. Neuroscience
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24 July 2015progenitors diﬀerentiate into dopaminergic neurons
resulting in a marked reduction in the number of dopa-
mine neurons in N-cadherin knockout mice. Our ﬁnding
of increased N-cadherin expression by 1,25(OH)2D3
in vitro is therefore consistent with the potential role this
agent plays in diﬀerentiating dopamine neurons. This
proposal is strengthened by our additional ﬁnding of a
decrease in N-cadherin protein in developing mesen-
cephalon from DVD-deﬁcient embryos. In fact it would
appear that DVD-deﬁciency phenocopies N-cadherin
knockout animals in that there is reduced N-cadherin,
increased proliferation and reduced TH (Table 1). One
caveat to this proposal, however, is that we do not know
whether N-cadherin is reduced speciﬁcally in developing
dopaminergic neurons.
CONCLUSION
In this study we clearly demonstrate that 1,25(OH)2D3
enhances TH expression in a VDR-expressing
neuroblastoma cells and importantly this eﬀect is
reversed when vitamin D is removed from the
developing brain. These ﬁndings strongly suggest that
1,25(OH)2D3 is a direct diﬀerentiation agent for
dopaminergic neurons. Schizophrenia is regarded as a
neurodevelopmental disease and alterations in the early
ontogeny of dopamine systems have been proposed to
be a central etiological feature of the disease (Eyles
et al., 2012). The direct modulation of TH by
1,25(OH)2D3 as demonstrated here might help us to bet-
ter understand the etiology for the epidemiological link
between DVD-deﬁciency and schizophrenia.
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